



Sheet 1 of 3

**INFORMATION DISCLOSURE STATEMENT  
IN AN APPLICATION**

(Use several sheets if necessary)

Docket No. (optional) 010094.05	Application Number: 10/826,445
Applicant: Tian et al.	
Filing Date: Apr. 16, 2004	Group Art Unit: (as yet unknown)

**U.S. PATENT DOCUMENTS**

Examiner Initial	Cite No. <sup>1</sup>	Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
B.K.	A1	US 3,987,035	1976	Rinehart, Jr., et al.	260	239.3P	
	A2	US 4,261,989	1981	Sasaki et al.	424	244	
	A3	US 4,421,687	1983	Hasegawa et al.	260	239.3B	
	A4	US 4,421,688	1983	Muroi et al.	260	239.3B	
	A5	US 4,540,517	1985	Tanida et al.	260	239.3B	
	A6	US 5,387,584	1995	Schnur	514	183	
	A7	US 5,510,118	1996	Bosch et al.	424	489	
↓	A8	US 5,534,270	1996	De Castro	424	490	

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Cite No. <sup>1</sup>	Document Number	Date	Country	Class	Sub-class	Translation Enclosed?
B.K.	B1	WO 93/14215 A1	1993	PCT			n/a
	B2	WO 94/08578 A2	1994	PCT			n/a
	B3	WO 95/01342 A1	1995	PCT			n/a
↓	B4	WO 00/03737 A2	2000	PCT			n/a
↓	B5	WO 02/079167 A1	2002	PCT			n/a

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initial	Cite No. <sup>1</sup>	Details of Document	Translation enclosed?
B.K.	C1	Sasaki et al., <i>J. Antibiotics</i> 32 (8), 849-851 (1979), "Growth Inhibition of Virus Transformed Cells in Vitro and Antitumor Activity in Vivo of Geldanamycin and its Derivatives"	n/a
	C2	Muroi et al., <i>Tetrahedron</i> 37, 1123-1130 (1981), "The Structures of Macbecins I and II"	n/a
↓	C3	Omura et al., <i>J. Antibiotics</i> 37 (10), 1264-1267 (1984), "Chemical Modification and Antitumor Activity of Herbimycin A, 8,9-Epoxide, 7,9-Cyclic Carbamate, and 17- or 19-Amino Derivatives"	n/a

Examiner

Date considered

8/24/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.


<sup>1</sup> Applicant's unique citation designation number (optional).

Form PTO-1449		Docket No. (optional) 010094.05	Application Number: 10/826,445
<b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>		Applicant: Tian et al.	
(Use several sheets if necessary)		Filing Date: Apr. 16, 2004	Group Art Unit: (as yet unknown)

U.S. PATENT DOCUMENTS							
Examiner Initial	Cite No. <sup>1</sup>	Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
B.K.	A9	US 5,662,883	1997	Bagchi et al.	424	9.4	
	A10	US 5,932,566	1999	Schnur et al.	514	183	
	A11	US 6,015,659	2000	Welch et al.	435	1.2	
	A12	US 6,682,758	2004	Tabibi et al.	424	450	12/22/1999
↓	A13	US 2003/0114450 A1	2003	Santi et al.	514	234.5	8/5/2002

FOREIGN PATENT DOCUMENTS							
Examiner Initial	Cite No. <sup>1</sup>	Document Number	Date	Country	Class	Sub-class	Translation Enclosed?
B.K.	B6	WO 02/36574 A1	2002	PCT			n/a
	B7	WO 03/013430 A2	2003	PCT			n/a
	B8	WO 03/066005 A2	2003	PCT			n/a
	B9	JP 63-218620	1988	Japan			no
↓	B10	JP 04-046120	1990	Japan			no

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			
Examiner Initial	Cite No. <sup>1</sup>	Details of Document	Translation enclosed?
B.K.	C4	Shibata et al., J. Antibiotics 39 (11), 1630-1633 (1986), "The Structure and Cytocidal Activity of Herbimycin C"	n/a
	C5	Uehara et al., J. Antibiotics 41 (5), 831-834 (1988), "Effects of Herbimycin Derivatives on src Oncogene Function in Relation to Antitumor Activity"	n/a
	C6	Schnur et al., J. Med. Chem., 38, 3806-3812 (1995), "Inhibition of Oncogene Products p185 (erbB-2) in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives"	n/a
	C7	Schnur et al., J. Med. Chem., 38, 3813-3820 (1995), "erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure-Activity Relationships"	n/a
↓	C8	Jez et al., Chemistry & Biology, 10, 361-368 (2003), "Crystal Structure and Molecular Modeling of 17-DMAG in Complex with Human Hsp90"	n/a

Examiner	Date considered
	8/24/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

Form PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>	<i>Docket No. (optional)</i> 010094.05	<i>Application Number:</i> 10/826,445
	<i>Applicant:</i> Tian et al.	
	<i>Filing Date:</i> Apr. 16, 2004	<i>Group Art Unit:</i> (as yet unknown)

FOREIGN PATENT DOCUMENTS							
Examiner Initial	Cite No. <sup>1</sup>	Document Number	Date	Country	Class	Sub-class	Translation Enclosed?

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			
Examiner Initial	Cite No. <sup>1</sup>	Details of Document	Translation enclosed?
B.K.	C9	Carreras et al., <i>Anal. Biochem.</i> , 317 (1), 40-46 (June 2003), "Filter Binding Assay for the Geldanamycin-Heat Shock Protein 90 Interaction"	n/a
L	C10	Chemical Abstracts 110:231340 (abstract of JP 63-218620)	n/a
L	C11	Chemical Abstracts 117:63002 (abstract of JP 04-046120)	n/a

Examiner	Bruh KHL	Date considered
		8/24/04

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

**1** Applicant's unique citation designation number (optional).